🇺🇸 KYMRIAH in United States

5,421 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Cytokine Release Syndrome — 1,412 reports (26.05%)
  2. Pyrexia — 938 reports (17.3%)
  3. Malignant Neoplasm Progression — 540 reports (9.96%)
  4. Hypotension — 376 reports (6.94%)
  5. Hypogammaglobulinaemia — 367 reports (6.77%)
  6. Platelet Count Decreased — 365 reports (6.73%)
  7. Neurotoxicity — 364 reports (6.71%)
  8. White Blood Cell Count Decreased — 356 reports (6.57%)
  9. Lymphocyte Count Decreased — 352 reports (6.49%)
  10. Haemoglobin Decreased — 351 reports (6.47%)

Source database →

KYMRIAH in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is KYMRIAH approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for KYMRIAH in United States?

Masonic Cancer Center, University of Minnesota is the originator. The local marketing authorisation holder may differ — check the official source linked above.